Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ATF4 | P18848 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26445155 | 1.00 | CNR1 (0.41) | CNR1CNR2NPSR1TDP1KMT2A | |
| SCHEMBL24848310 | 0.86 | CNR1 (0.40) | CNR1CNR2NPSR1TDP1KMT2A | |
| SCHEMBL26445192 | 0.86 | CNR1 (0.40) | CNR1CNR2NPSR1TDP1KMT2A | |
| SCHEMBL29307069 | 0.84 | NPSR1 (0.37) | NPSR1KMT2AMEN1HCRTR2L3MBTL1 | |
| SCHEMBL17740999 | 0.82 | NPSR1 (0.58) | NPSR1KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL26445141 | 0.77 | SMN1; SMN2 (0.44) | CNR1CNR2KMT2AMEN1HCRTR2 | |
| SCHEMBL26445139 | 0.77 | SMN1; SMN2 (0.44) | CNR1CNR2KMT2AMEN1HCRTR2 | |
| SCHEMBL12424430 | 0.77 | NPSR1 (0.64) | NPSR1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL12384535 | 0.74 | RAB9A (0.43) | NPSR1HCRTR2RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL26445149 | 0.72 | CNR2 (0.52) | CNR1CNR2KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CNR1 2314/4885CNR2 716/4885NPSR1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.